Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACON vs CDT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACON Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 3–3 Matrix Metrics)

ACON Overall Winner 6-Pillar Tally: ACON 4 – 1 CDT (1 Tie) Matrix Metrics: ACON 3 – 3 CDT

As of Nov 20, 2026, Aclarion, Inc. (ACON) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ACON carries a Unified Composite Score of 42.2/100 (HOLD) at $1.22 (N/M Forward P/E, -10789.2% operating margin), whereas CDT carries 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ACON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile CDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACON vs CDT
ACON NASDAQ Head-to-Head Winner
Aclarion, Inc. Common Stock
Services-Medical Laboratories
$1.22
-13.92% 1D
Market Cap $3.7M
TTM Revenue $98,560
Forward P/E N/M
Beta / 30D Vol 1.36β · 87% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 30.0 Fund 55.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.1%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $1.66 · SMA50: $2.06
CDT NASDAQ
CDT Equity Inc. Common Stock
Pharmaceutical Preparations
$0.23
-13.89% 1D
Market Cap $507,528
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -17.75β · 10175% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -58.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $0.31 · SMA50: $0.40

6-Pillar Scorecard Institutional Category Breakdown (ACON 4 – 1 CDT)

Columns: Metric · ACON · CDT
1. Valuation Multiples ACON
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 37.7x N/M
2. Growth & Scale ACON
Revenue Growth (YoY) +78.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $98,560 N/A
Market Cap $3.7M $507,528
3. Profitability & Quality CDT
Gross Margin 29.1% N/A
Operating Margin -10789.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -74.1% -69.7%
4. Balance Sheet & Cash Flow ACON
Cash Generation (TTM) -$7.5M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.13 Book/Sh · -74.1% ROE $435,000 Net Debt (0.01x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACON
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Health Information Services Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACON (3) vs CDT (3)
Institutional Metric ACON CDT Criterion Row Edge
Market Capitalization
Scale
$3.7M $507,528 Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+78.1% +0.0% Higher Growth ACON
Operating Margin (TTM)
Profitability
-10789.2% 0.0% Higher Margin CDT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-74.1% -69.7% Higher ROE CDT
52-Week Range Position
Momentum
0% ($1–$9) 2% ($0–$11) Stronger Trend CDT
Beta / 30D Volatility
Risk Regime
1.36β · 87% Vol -17.75β · 10175% Vol Lower Realized Risk ACON
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 31.6 / 100 (SELL) Higher Composite ACON
Trailing 12M Revenue (USD)
Operating Scale
$98,560 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 37.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.5M ($5.13 Book/Sh · -74.1% ROE) N/A ($435,000 Net Debt (0.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDT +113.62 pp
ACON: -36.83% · CDT: +76.79%
3M Horizon ACON +36.71 pp
ACON: -54.05% · CDT: -90.76%
6M Horizon ACON +16.18 pp
ACON: -61.92% · CDT: -78.1%
1Y Horizon ACON +7.6 pp
ACON: -79.18% · CDT: -86.78%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACON vs CDT. Trailing 12-month operating profitability (ACON -10789.2% vs CDT 0.0%) and valuation multiples (ACON N/M vs CDT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$98,560
Gross Margin29.1%
Op. Margin-10789.2%
ROE / Fwd P/E-74.1% · N/M
CDT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACON UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDT BREAKDOWN
163d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACON Moat Profile Cyclical / Execution-Driven Positioning
Health Information Services Operator
Competes within the Health Information Services value chain with $3.7M market capitalization and -10789.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $507,528 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACON vs CDT Key Questions & Quantitative Answers

As of Nov 20, 2026, Aclarion, Inc. (ACON) is the stronger overall head-to-head candidate over CDT Equity Inc. (CDT) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ACON carries a Unified Composite Score of 42.2/100 (HOLD) at $1.22 (N/M Forward P/E, -10789.2% operating margin), whereas CDT carries 31.6/100 (SELL) at $0.23 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ACON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile CDT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ACON leads the Growth & Scale pillar: ACON posts +78.1% YoY revenue growth and +0.0% YoY earnings growth on $98,560 TTM revenue (29.1% gross margin, -10789.2% operating margin), compared with CDT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ACON generates $98,560 in USD-normalized revenue versus N/A for CDT. In operating R&D and SG&A reinvestment, ACON deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CDT.

ACON screens cheaper on headline valuation multiples. ACON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.7x EV/Revenue (unreported FCF margin), whereas CDT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACON (-74.1% ROE) versus CDT (-69.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ACON carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 87% Vol realized risk). By comparison, CDT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (-17.75β · 10175% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.